Overview

Study of Tedizolid Phosphate in Adolescents With Complicated Skin and Soft Tissue Infection (cSSTI) (MK-1986-012)

Status:
Completed
Trial end date:
2018-09-17
Target enrollment:
Participant gender:
Summary
The purpose of the study is to compare the safety of intravenous (IV) and/or oral 6-day 200 mg tedizolid phosphate with 10-day comparator in participants 12 to <18 years with cSSTI.
Phase:
Phase 3
Details
Lead Sponsor:
Cubist Pharmaceuticals LLC
Treatments:
Anti-Bacterial Agents
Antibiotics, Antitubercular
Aztreonam
Cefazolin
Cephalexin
Clindamycin
Linezolid
Metronidazole
Oxazolidinones
Tedizolid
Torezolid
Torezolid phosphate
Vancomycin